Shopping Cart
Remove All
Your shopping cart is currently empty
Timolumab (BTT 1023), a fully human antibody targeting vascular adhesion protein-1 (VAP-1), attenuates fibrosis in a mouse model of liver injury and may be used to study primary sclerosing cholangitis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | In Stock | In Stock | |
| 5 mg | $795 | In Stock | In Stock | |
| 10 mg | $1,260 | - | In Stock | |
| 25 mg | $1,870 | - | In Stock | |
| 50 mg | $2,520 | - | In Stock |
| Description | Timolumab (BTT 1023), a fully human antibody targeting vascular adhesion protein-1 (VAP-1), attenuates fibrosis in a mouse model of liver injury and may be used to study primary sclerosing cholangitis. |
| In vitro | Timolumab binds to human VAP-1, thereby inhibiting it from functioning as an adhesion molecule. It also recognizes VAP-1 from other primates and rabbits, but does not cross-react to VAP-1 from rats and mice. [2] |
| Synonyms | BTT1023, BTT 1023; Anti-Human AOC3 Recombinant Antibody, BTT 1023 |
| Cas No. | 1073538-99-4 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.